TY - JOUR
T1 - Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors
AU - Sutton, Lesley-Ann
AU - Young, Emma
AU - Baliakas, Panagiotis
AU - Hadzidimitriou, Anastasia
AU - Moysiadis, Theodoros
AU - Plevova, Karla
AU - Rossi, Davide
AU - Kminkova, Jana
AU - Stalika, Evangelia
AU - Pedersen, Lone Bredo
AU - Malcikova, Jitka
AU - Agathangelidis, Andreas
AU - Davis, Zadie
AU - Mansouri, Larry
AU - Scarfò, Lydia
AU - Boudjoghra, Myriam
AU - Navarro, Alba
AU - Muggen, Alice F
AU - Yan, Xiao-Jie
AU - Nguyen-Khac, Florence
AU - Larrayoz, Marta
AU - Panagiotidis, Panagiotis
AU - Chiorazzi, Nicholas
AU - Niemann, Carsten Utoft
AU - Belessi, Chrysoula
AU - Campo, Elias
AU - Strefford, Jonathan C
AU - Langerak, Anton W
AU - Oscier, David
AU - Gaidano, Gianluca
AU - Pospisilova, Sarka
AU - Davi, Frederic
AU - Ghia, Paolo
AU - Stamatopoulos, Kostas
AU - Rosenquist, Richard
AU - ERIC, the European Research Initiative on CLL
N1 - Copyright© Ferrata Storti Foundation.
PY - 2016/8
Y1 - 2016/8
N2 - We report on markedly different frequencies of genetic lesions within subsets of chronic lymphocytic leukemia patients carrying mutated or unmutated stereotyped B-cell receptor immunoglobulins in the largest cohort (n=565) studied for this purpose. By combining data on recurrent gene mutations (BIRC3, MYD88, NOTCH1, SF3B1 and TP53) and cytogenetic aberrations, we reveal a subset-biased acquisition of gene mutations. More specifically, the frequency of NOTCH1 mutations was found to be enriched in subsets expressing unmutated immunoglobulin genes, i.e. #1, #6, #8 and #59 (22-34%), often in association with trisomy 12, and was significantly different (P<0.001) to the frequency observed in subset #2 (4%, aggressive disease, variable somatic hypermutation status) and subset #4 (1%, indolent disease, mutated immunoglobulin genes). Interestingly, subsets harboring a high frequency of NOTCH1 mutations were found to carry few (if any) SF3B1 mutations. This starkly contrasts with subsets #2 and #3 where, despite their immunogenetic differences, SF3B1 mutations occurred in 45% and 46% of cases, respectively. In addition, mutations within TP53, whilst enriched in subset #1 (16%), were rare in subsets #2 and #8 (both 2%), despite all being clinically aggressive. All subsets were negative for MYD88 mutations, whereas BIRC3 mutations were infrequent. Collectively, this striking bias and skewed distribution of mutations and cytogenetic aberrations within specific chronic lymphocytic leukemia subsets implies that the mechanisms underlying clinical aggressiveness are not uniform, but rather support the existence of distinct genetic pathways of clonal evolution governed by a particular stereotyped B-cell receptor selecting a certain molecular lesion(s).
AB - We report on markedly different frequencies of genetic lesions within subsets of chronic lymphocytic leukemia patients carrying mutated or unmutated stereotyped B-cell receptor immunoglobulins in the largest cohort (n=565) studied for this purpose. By combining data on recurrent gene mutations (BIRC3, MYD88, NOTCH1, SF3B1 and TP53) and cytogenetic aberrations, we reveal a subset-biased acquisition of gene mutations. More specifically, the frequency of NOTCH1 mutations was found to be enriched in subsets expressing unmutated immunoglobulin genes, i.e. #1, #6, #8 and #59 (22-34%), often in association with trisomy 12, and was significantly different (P<0.001) to the frequency observed in subset #2 (4%, aggressive disease, variable somatic hypermutation status) and subset #4 (1%, indolent disease, mutated immunoglobulin genes). Interestingly, subsets harboring a high frequency of NOTCH1 mutations were found to carry few (if any) SF3B1 mutations. This starkly contrasts with subsets #2 and #3 where, despite their immunogenetic differences, SF3B1 mutations occurred in 45% and 46% of cases, respectively. In addition, mutations within TP53, whilst enriched in subset #1 (16%), were rare in subsets #2 and #8 (both 2%), despite all being clinically aggressive. All subsets were negative for MYD88 mutations, whereas BIRC3 mutations were infrequent. Collectively, this striking bias and skewed distribution of mutations and cytogenetic aberrations within specific chronic lymphocytic leukemia subsets implies that the mechanisms underlying clinical aggressiveness are not uniform, but rather support the existence of distinct genetic pathways of clonal evolution governed by a particular stereotyped B-cell receptor selecting a certain molecular lesion(s).
KW - Journal Article
U2 - 10.3324/haematol.2016.141812
DO - 10.3324/haematol.2016.141812
M3 - Journal article
C2 - 27198719
SN - 0390-6078
VL - 101
SP - 959
EP - 967
JO - Haematologica
JF - Haematologica
IS - 8
ER -